Lumican deficiency promotes pulmonary arterial remodeling.

[1]  J. Monboisse,et al.  Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression , 2020, Frontiers in Oncology.

[2]  Cheng-Ta Yang,et al.  Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin , 2018, Cell Death & Disease.

[3]  J. Pang,et al.  Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[4]  Pin-i Chen,et al.  Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-&bgr; in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[5]  W. Kao,et al.  Lumican Peptides: Rational Design Targeting ALK5/TGFBRI , 2017, Scientific Reports.

[6]  Y. Yeh,et al.  Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase , 2015, PloS one.

[7]  J. Garcia,et al.  Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[8]  Huamin Wang,et al.  Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery , 2014, Clinical Cancer Research.

[9]  N. Karamanos,et al.  Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[10]  W. Seeger,et al.  Novel and emerging therapies for pulmonary hypertension. , 2014, American journal of respiratory and critical care medicine.

[11]  S. Saika,et al.  Lumican Binds ALK5 to Promote Epithelium Wound Healing , 2013, PloS one.

[12]  W. Kao,et al.  Lumican Exhibits Anti-Angiogenic Activity in a Context Specific Manner , 2013, Cancer Microenvironment.

[13]  J. Dubois-Randé,et al.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. , 2013, American journal of respiratory cell and molecular biology.

[14]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[15]  P. Katonis,et al.  Lumican regulates osteosarcoma cell adhesion by modulating TGFβ2 activity. , 2011, The international journal of biochemistry & cell biology.

[16]  W. Kao,et al.  Impaired skin wound healing in lumican‐null mice , 2010, The British journal of dermatology.

[17]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[18]  Chengqun Huang,et al.  NOTCH3 SIGNALING IS REQUIRED FOR THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION , 2009, Nature Medicine.

[19]  N. Morrell,et al.  Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.

[20]  A. Tsatsakis,et al.  Lumican, a small leucine‐rich proteoglycan , 2008, IUBMB life.

[21]  W. Seeger,et al.  Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[22]  M. Rabinovitch.  Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[23]  S. Oparil,et al.  Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[24]  P. Sehgal,et al.  Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[25]  A. Tsatsakis,et al.  Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells , 2008, The FEBS journal.

[26]  T. Kietzmann,et al.  Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. , 2007, Molecular biology of the cell.

[27]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[28]  Wei Li,et al.  Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing. , 2005, Investigative ophthalmology & visual science.

[29]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[30]  F. Antonicelli,et al.  The small leucine-rich proteoglycan lumican inhibits melanoma progression. , 2004, Experimental cell research.

[31]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[32]  N. Morrell,et al.  Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.

[33]  Reynold A Panettieri,et al.  PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[34]  B. A. Austin,et al.  Altered collagen fibril formation in the sclera of lumican-deficient mice. , 2002, Investigative ophthalmology & visual science.

[35]  Y. Sugisaki,et al.  Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. , 2002, Experimental and molecular pathology.

[36]  T. Ishiwata,et al.  Effects of the extracellular matrix on lumican expression in rat aortic smooth muscle cells in vitro , 2001, The Journal of pathology.

[37]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[38]  E. Takashi,et al.  Expression and localization of lumican in the ischemic and reperfused rat heart. , 2001, Japanese circulation journal.

[39]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[40]  S. Saika,et al.  Role of Lumican in the Corneal Epithelium during Wound Healing* , 2000, The Journal of Biological Chemistry.

[41]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[42]  P. Roughley,et al.  Expression of lumican in human lungs. , 1998, American journal of respiratory cell and molecular biology.

[43]  J. Hassell,et al.  Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. , 1993, Experimental eye research.

[44]  J. Hassell,et al.  Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated. , 1992, The Journal of biological chemistry.

[45]  J. Vergnes,et al.  cDNA to chick lumican (corneal keratan sulfate proteoglycan) reveals homology to the small interstitial proteoglycan gene family and expression in muscle and intestine. , 1992, The Journal of biological chemistry.

[46]  G. Conrad,et al.  Focus on molecules: lumican. , 2006, Experimental eye research.